National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Talazoparib (Talzenna®) HTA ID: 19032

Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.

NCPE Assessment Process Complete
Rapid review commissioned 19/08/2019
Rapid review completed 03/09/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talazoparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 09/09/2019
Pre-submission consultation with Applicant 02/12/2019
Initial submission received from Applicant 02/03/2020
Complete submission received from Applicant 06/03/2020
Preliminary review sent to Applicant 24/04/2020
NCPE assessment re-commenced 05/06/2020
Factual accuracy sent to Applicant 14/08/2020
NCPE assessment re-commenced 21/08/2020
NCPE assessment completed 18/09/2020
NCPE assessment outcome The NCPE recommends that talazoparib (Talzenna®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.